About HBOT Science

Editorial standards

Every claim on this site is anchored to a peer-reviewed source or recognised clinical authority (UHMS, Cochrane, FDA, professional society guidelines). References are verified at build time against the CrossRef DOI registry — broken or invented citations cannot ship.

Quantitative claims (effect sizes, sample numbers, durations) are reproduced directly from the cited source. We do not paraphrase numbers, round percentages, or summarise outcomes in ways that lose the underlying caveats.

Where evidence is preliminary, single-source, or contested, the site says so plainly. We use a three-tier evidence framework — Level A (multiple high-quality RCTs or systematic reviews), Level B (one strong RCT or consistent meta-analytic evidence), Level C (case-level, small-cohort, or translational evidence). Investigational uses are labelled investigational. Claims with insufficient evidence are not made at all.

Evidence framework

The site organises HBOT indications into two tiers reflecting different evidence bases.

FDA-approved indications are the fourteen conditions recognised by the Undersea and Hyperbaric Medical Society (UHMS) and covered by Medicare and Medicaid in the United States as standard or adjunctive treatment. Each is supported by Level A or Level B evidence. Treatment protocols for these conditions are well-established and clinically validated.

Emerging-evidence indications are conditions where peer-reviewed clinical evidence supports investigational use of HBOT, but where the evidence does not yet meet the threshold for FDA approval or UHMS recognition. These are typically supported by Level B or Level C evidence — single research groups awaiting independent replication, pilot studies awaiting full trials, or case-level evidence in defined sub-populations. They are presented for clinical context. Treatment decisions involving emerging-evidence indications require individual patient evaluation and are not standard of care.

Editorial publisher

HBOT Science is published by IN2050 Ltd, a Cyprus-registered company (HE416406) operating in the wellness hospitality sector. IN2050 has commercial interests in HBOT services. Editorial decisions on this site are made independently of those commercial interests.

Corrections and updates

Errors of fact, citation, or interpretation are corrected when identified. Significant corrections are noted on the affected page and in the site's commit history, which is publicly available. Minor edits (typography, spelling, formatting) are applied without notice.

The site is updated as new peer-reviewed evidence becomes available. Indications may move between evidence tiers as evidence strengthens or new trials report results. Where the editorial framing of an indication changes substantively, the change is reflected in the commit history.

To report an error or suggest a correction, contact: [email protected]

Scope and limits

This site provides reference information on hyperbaric oxygen therapy. It does not:

• Provide individual medical advice or treatment recommendations.
• Diagnose conditions or substitute for clinical evaluation by a qualified practitioner.
• Endorse, recommend, or compare specific HBOT providers, clinics, or products.
• Provide pricing, commercial information, or guidance on accessing treatment.
• Provide legal advice on HBOT regulation, licensing, or compliance.
• Provide insurance or reimbursement guidance.
• Provide advice on opening, operating, or designing HBOT facilities.

Patients seeking HBOT for any indication should consult a qualified physician or hyperbaric medicine specialist. Treatment decisions require evaluation of individual medical history, comorbidities, and concurrent medications.